Apotheca Biosciences (PCFP) S-1/A 15 Mar 19 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Oct. 31, 2018
Document And Entity Information
Entity Registrant Name	Apotheca Biosciences, Inc.
Entity Central Index Key	0001632053
Document Type	S-1
Document Period End Date	Oct. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Ex Transition Period	false
Document Fiscal Year Focus	2019

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)	Oct. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017
Current assets
Cash	$ 168,462	$ 0	$ 0	$ 489
Deposits and prepaids	6,000	0
Total Assets	174,462	0	0	489
Current liabilities
Accounts payable and accrued liabilities				4,601
Accounts payable	34,024	295	17,660
Accounts payable - related party	3,724	0
Accrued liabilities	51,053	30,000	0
Notes payable	18,600	0
Loans payable			157,455
Loans payable - related parties			47,134	28,534
Related party advances	0	1,947
Derivative liabilities	579,660	0
Convertible note payable, net of discount of $291,687	8,313	0
Total liabilities	695,374	32,242	222,249	33,135
Shareholders' Deficit
Common stock: 600,000,000 authorized; $0.001 par value at October 31, 2018 and 200,000,000 authorized, $0.0001 par value at April 30, 2018 113,914,000 and 111,314,000 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively	113,914	6,000	50,340	50,340
Additional paid in capital	(303,187)	0	17,242	11,065
Shares to be issued, common shares	73,700	0
Accumulated deficit	(405,339)	(38,242)	(289,831)	(94,051)
Total Shareholders' Deficit	(520,912)	(32,242)	(222,249)	(32,646)
Total Liabilities and Shareholders' Deficit	$ 174,462	$ 0	$ 0	$ 489

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)	Oct. 31, 2018USD ($)$ / sharesshares
Statement of Financial Position [Abstract]
Common stock, par value per share | $ / shares	$ 0.001
Common stock, shares authorized	600,000,000
Common stock, shares issued	113,914,000
Common stock, shares outstanding	113,914,000
Discount | $	$ 291,687

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating Expenses
Personnel expenses	45,000	120,000
General and administrative	110,763	127,984	$ 45,694	$ 14,771
Impairment of deposit on license			79,975	0
License and permits			62,480
Total operating expenses	155,763	247,984	188,149	14,771
Net loss from operations	(155,763)	(247,984)	(188,149)	(14,771)
Other income (expense):
Interest expense	(9,695)	(9,695)	(7,631)	(3,015)
Gain on settlement of liability	156,000	156,000
Derivative expense	(303,660)	(303,660)
Total other income (expense)	(157,355)	(157,355)	(7,631)	(3,015)
Net Income	$ (313,118)	$ (405,339)	$ (195,780)	$ (17,786)
Basic and diluted loss per share	$ (0.01)	$ (0.01)	$ 0	$ 0
Weighted average number of shares outstanding	113,769,556	77,648,826	50,340,000	50,340,000

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, shares at Jan. 31, 2016	50,340,000
Balance, value at Jan. 31, 2016	$ 50,340		$ (76,265)	$ (25,925)
Imputed Interest Expense		3,015		3,015
Shareholder Contributions		8,050		8,050
Net loss			(17,786)	$ (17,786)
Balance, shares at Jan. 31, 2017	50,340,000			50,340,000
Balance, value at Jan. 31, 2017	$ 50,340	11,065	(94,051)	$ (32,646)
Imputed Interest Expense		2,677		2,677
Shareholder Contributions		3,500		3,500
Net loss			(195,780)	$ (195,780)
Balance, shares at Jan. 31, 2018	50,340,000			50,340,000
Balance, value at Jan. 31, 2018	$ 50,340	$ 17,242	$ (289,831)	$ (222,249)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (405,339)	$ (195,780)	$ (17,786)
Adjustments to reconcile net loss to net cash used by operating activities
Change in fair value of derivative liabilities	303,660
Stock issued in exchange for services	6,000
Gain on settlement of liability	(156,000)
Amortization of debt discount	8,313
Imputed Interest Expense		2,677	3,015
Expenses paid by a related party		3,500	8,050
Impairment of license deposit		79,975	0
License expense		62,480	0
Changes in operating assets and liabilities:
Prepaid expenses	(6,000)
Accounts payable	34,024
Accounts payable - related party	3,724
Accrued liabilities	62,840
Accounts payable and accrued expenses		13,059	3,380
Net Cash Used in Operating Activities	(149,138)	(34,089)	(3,341)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deposit on license		(142,455)	0
Net Cash Used by Investing Activities		(142,455)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received for subscription agreements	73,700
Proceeds from convertible notes payable	243,900
Proceeds from related party loan		18,600	472
Proceeds from unrelated party loan		157,455
Net Cash Provided in Financing Activities	317,600	176,055	472
Net increase in cash and cash equivalents	168,462	(489)	(2,869)
Cash and cash equivalents, beginning of period	0	489	3,358
Cash and cash equivalents, end of period	168,462	0	489
Supplemental disclosure of cash flow information:
Cash paid for income taxes		0	0
Cash paid for interest	0	$ 0	$ 0
Supplemental disclosure of non-cash financing activities:
Shares issued to settle a liability	$ 1,300,000

Organization And Basis Of Prese

Organization And Basis Of Presentation	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Accounting Policies [Abstract]
Organization and Basis of Presentation	NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION Apotheca Biosciences is a medical device company developing engineering and device solutions for cannabinoid medical technologies. The company is incorporated in Nevada as a Corporation with principal business in Saint Petersburg, FL. The company develops, license and market cannabinoid technologies to various market sectors. Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our technologies to the world’s aging population. The last two decades of research have brought a tremendous improvement in knowledge of the endocannabinoid system (eCB system) components and functions under physiological and pathological conditions. The eCB is a neuromodulatory system consists of two subtypes of cannabinoid receptors, CB1 and CB2 Vision Apotheca Biosciences is positioning to be global leader in discovering new cannabinoid medical technologies to make life better and healthier Mission To contribute to human welfare through innovative biomedical engineering solutions; to deliver cannabinoid actives that relieve pain, restore health, and longevity of millions of patients around the world. Core values: · Bring cost-effective and meaningful medical care to patients · Build an environment of creativity and transform new ideas into breakthrough technologies and devices · Pursue innovative engineering solutions that challenge established thinking · Change and act with speed via scientific collaboration, partnership and a winning spirit Apotheca Biosciences, Inc. (the "Company") was originally incorporated in the State of Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. On June 2, 2017 the Company entered into a short form Merger Agreement with the Company’s wholly owned subsidiary in order to effect the change of their corporate name. The name change was effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Cannabis Leaf Incorporated., a Nevada Corporation (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). Pursuant to an Agreement of Merger, dated June 2, 2017, between the Company and the Subsidiary, effective June 7, 2017, the Subsidiary merged with and into the Company and ceased to exist (the “Merger”). Pacificorp Holdings, Ltd was the surviving entity and adopted the name of the subsidiary, Cannabis Leaf Incorporated. On March 6, 2018 an Agreement and Plan of Merger (the "Agreement") was made and entered into as of March 6, 2018 by and among Cannabis Leaf Incorporated (“CLI”) and Apotheca. The respective Boards of Directors of CLI and Apotheca determined that it was in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI (the "Merger"), with Apotheca as the surviving entity post-Merger, the respective Boards of Directors of CLI and the Apotheca approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents. On August 2, 2018 giving Effect to the Merger These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in United States (US) dollars. The Company has not produced any revenue from its principal business and is a development stage company. The Company has changed it business from a license holder with Affordable Green LLC of Tacoma WA to a cannabis bioscience company. Additionally, the Company has changed its name as a result of a merger with the Company’s wholly owned subsidiary Apotheca Biosciences, Inc. as a result of this merger Cannabis Leaf adopted the name of the subsidiary. The comparative balance sheet is the balance sheet audited as of April 30, 2018 for Apotheca Private.	NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION Cannabis Leaf, Inc. (the "Company") was incorporated in the State of Nevada on October 6, 2014, as Pacificorp Holdings, Ltd. The Company was organized to develop and explore mineral properties in the State of Nevada. These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in United States (US) dollars. The Company has not produced any revenue from its principal business and is an exploration stage company. The Company has changed it business from a mining and exploration company and entered in to an exclusive license agreement with Affordable Green LLC of Tacoma WA. Additionally, the Company has changed its name as a result of a merger with the Company's wholly owned subsidiary Cannabis Leaf, Inc. as a result of this merger Pacificorp adopted the name of the subsidiary. There were no assets purchased or shares exchanged. Forward Split On June 26, 2017 FINRA approved a 6 to 1 forward split, all numbers reflected in the Financial Statements account for the forward split and have been retroactively adjusted.

Significant Accounting Policies

Significant Accounting Policies	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited and have not been reviewed. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. Fair Value of Financial Instruments The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments. Basic and Diluted Earnings Per Share Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share there were no potentially dilutive securities. New Accountin Pronouncements In February 2016, FASB issued ASC 842 that requires lessees to recognize lease assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months. The update, which supersedes existing lease guidance, will continue to classify leases as either finance or operating, with the classification determining the pattern of expense recognition in the income statement. The ASU will be effective for annual and interim periods beginning January 1, 2019, with early adoption permitted, and is applicable on a modified retrospective basis with various optional practical expedients. The Company is assessing the impact of this standard. In May 2014, ASU 2014-09 was issued related to revenue from contracts with customers. The ASU was further amended in August 2015, March 2016, April 2016, and May 2016 by ASU 2015-14, 2016-08, 2016-10 and 2016-12. The new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition. In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted. The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.	NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP") and presented in US dollars. The fiscal year end is January 31. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. Cash and Cash Equivalents The Company considers all liquid investments with a maturity of three months or less from the date of purchase that are readily convertible into cash to be cash equivalents. As of January 31, 2018 and 2017, cash and cash equivalents was $0 and $498, respectively. Financial Instruments The Company's financial instruments consist primarily of cash, accounts payable and accrued liabilities, notes payable and due to related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments. Deferred Income Taxes and Valuation Allowance The Company accounts for income taxes under ASC 740, "Income Taxes". Net Loss Per Share of Common Stock The Company follows - ASC Topic 260, "Earnings per Share" Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company's earnings subject to anti-dilution limitations. In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact. For the year ended January 31, 2018 and 2017, the Company did have any potentially dilutive securities. Contingencies The Company follows ASC 450-20, "Loss Contingencies" Revenue Recognition , "Revenue from Contracts with Customers." Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)", "Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date," Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing," "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients," In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" In January 2017, the FASB issued ASU No. 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business." Management has considered all recent accounting pronouncements issued. The Company's management believes that these recent pronouncements will not have a material effect on the Company's financial statements.

Merger

Merger	8 Months Ended
	Oct. 31, 2018
Business Combinations [Abstract]
Merger	NOTE 3 – MERGER On March 6, 2018 an Agreement and Plan of Merger was made and entered into as of March 6, 2018 by and among Cannabis Leaf (CLI) and Apotheca. The respective Boards of Directors of CLI and Apotheca have determined that it is in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI , with Apotheca (post name change from cannabis Leaf) as the surviving entity post-Merger, upon the terms and subject to the conditions set forth herein; the respective Boards of Directors of CLI and the Apotheca have approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents. At the Effective Time, by virtue of the Merger and without any action on the part of CLI or Apotheca or any holder of capital stock of CLI or Apotheca: (a) Capital Stock of CLI. Each issued and outstanding share of capital stock of shall by virtue of the Merger and without any action on the part of any holder thereof, be converted into and shall be existing as one share of CLI's common stock without need of re-issuance. Such shares shall thereafter constitute all of the issued and outstanding capital stock of the Surviving Corporation being Apotheca. (b) Conversion of CLI Stock:(i) Each share of CLI Common Stock issued and outstanding immediately prior to the Effective Time (individually a "Share" and collectively the "Shares"), shall be considered shares of Apotheca as the surviving entity as set forth below (the "Merger Consideration"). (ii) At the Effective Time, each Share held by CLI as treasury stock or held by CLI, or any Subsidiary of CLI, immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of CLI continue to exist as shares of Apotheca as the surviving entity without further consideration with respect thereto. (iii) At the Effective Time, each Share of the Treasury Stock as Authorized Shares but unissued Shares of CLI shall become Treasury Shares but unissued Shares of Apotheca, with no change the authorized shares which were in effect immediately prior to the Effective Time. (iv) At the Effective Time, Apotheca as the surviving entity and in exchange for the acquisition of Apotheca shall be issued as such exchange for control and merger the amount of sixty million (60,000,000) shares of Apotheca as the surviving Company in the form of common shares to be distributed as set forth by Apotheca at its direction on a schedule set forth for issuance. Such shares shall be considered the Merger Control Shares and shall represent approximately sixty percent of the then post-issuance control of CLI post-merger. (v) At the time of exchange in such transaction, there is as certified by CLI, its board of directors and management, exist no convertible or other debt with claims or rights superior for the issuance of any shares of common stock in CLI, and no such claims need be recognized by Apotheca as debt of the surviving entity. Any such debt must have been and was not disclosed to Apotheca before this transaction, and the existing of such debt or claims is a liability of the prior management of CLI and not of Apotheca as the surviving entity. Closing. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to its terms, the closing of the Merger on May 15, 2018 Effective Time of the Merger. Subject to the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a certificate of merger in substantially the form required by the Secretary of State of Nevada to be executed and filed with the Secretary of State of the State of Nevada, and (b) take all such other and further actions as may be required by the NRS or other applicable Law to make the Merger effective. The Merger shall become effective as of the date and time of the filing of the Nevada Certificate of Merger or at such later date or time as may be agreed by CLI and CLI in writing and specified in the Nevada Certificate of Merger in accordance with relevant provisions of the NRS. The date and time of such effectiveness are referred to herein as the Effective Time. On August 2, 2018 giving Effect to the Merger The unaudited pro forma combined condensed financial statements were prepared using the acquisition method of accounting as outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations The acquisition of a private operating company by a nonoperating public shell corporation typically results in the owners and management of the private company having actual or effective voting and operating control of the combined company. A public shell reverse acquisition is viewed as a capital transaction in substance, rather than a business combination. As a result, it should be accounted for as a reverse recapitalization equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation accompanied by a recapitalization. This accounting treatment is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization. Common Stock Shares Amount Additional Paid in Capital Shares to be issued Accumulated (Deficit) Total Balances, February 26, 2018 - $ - $ - $ - $ - $ - Shares issued by Apotheca in exchange for services ($.001 par value) 60,000,000 6,000 - - - 6,000 Recapitalization on August 2, 2018 51,314,000 105,314 (1,444,587 ) (1,339,273 ) Shares issued in satisfaction of accrued liability (license settlement) 2,600,000 2,600 1,141,000 1,144,000 Shares to be issued 73,700 73,700 Net loss from February 26, 2018 through October 31, 2018 (405,339 ) (405,339 ) Balances, October 31, 2018 113,914,000 $ 113,914 $ (303,187 ) $ 73,7000 $ (405,339 ) $ (520,912 )

Going Concern

Going Concern	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 4 – GOING CONCERN The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern.	NOTE 3 – GOING CONCERN The Company accounts for going concern matters under the guidance of ASU 2014-15, "Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize it assets and discharge its liabilities in the normal course of business. As of January 31, 2018, the Company has incurred losses totaling $289,831 since inception, has not yet generated significant revenue from its operations, and will require additional funds to maintain our operations. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through continued financial support from its shareholders, the issuance of debt securities and private placements of common stock. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Deposit on License Impairment

Deposit on License Impairment	12 Months Ended
	Jan. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Deposit on License Impairment	NOTE 4 - DEPOSIT ON LICENSE IMPAIRMENT As of January 31, 2018, the Company has paid a total of $142,455 as a deposit on their License with Affordable Green LLC. During the year ended January 31, 2018, the Company recorded impairment charges related to the deposit paid to Affordable Green LLC totaling $79,975 and expensed $62,480, as the Company failed to make the requisite payments under the terms of the agreement. Additionally, there is not an amended or new agreement currently in place. The Company is continuing to make payments on the license and is recognizing costs related to these activities as expenses during the period in which they are incurred. All funds used for the deposit on license were received by way of short term loans that bear a 5% annual interest rate.

Note Payable From Related Party

Note Payable From Related Party	12 Months Ended
	Jan. 31, 2018
Related Party Transactions [Abstract]
Note Payable from Related Party	NOTE 5 – NOTE PAYABLE FROM RELATED PARTY As of January 31, 2018 and 2017, the Company received advances totaling $47,134 and $28,534, respectively from related parties, the advances are unsecured, of which $28,534 is non-interest bearing and is due upon demand giving 30 days written notice to the borrower. A balance of $18,600 was received from a related party and bares an interest rate of 5% per annum, and is due upon demand giving 30 days written notice to the borrower. The Company has recorded imputed interest of $2,677 and accrued interest of $710 respectively for the year ended January 31, 2018.

Accounts Payable - Related Part

Accounts Payable - Related Party	8 Months Ended
	Oct. 31, 2018
Notes to Financial Statements
Accounts Payable - Related Party	NOTE 5 – ACCOUNTS PAYABLE – RELATED PARTY As of October 31, 2018, the Company has an accounts payable balance of $3,724 to a related party. The Company has a lease agreement with the related party, Nuvus Gro Corp, in which the Company pays $6,408 per month for office space. On October 15, 2018, the Company paid $2,684 towards the $6,408 rent due for October leaving a balance of $3,724. See Note 10.

Related Party Contributions

Related Party Contributions	12 Months Ended
	Jan. 31, 2018
Related Party Transactions [Abstract]
Related Party Contributions	NOTE 6 – RELATED PARTY CONTRIBUTIONS During the year ended January 31, 2018 and 2017 the Company received contributions totaling $3,500 and $8,050, respectively from a related party, these contributions are not to be repaid and are recorded under additional paid in capital.

Accrued Liabilities

Accrued Liabilities	8 Months Ended
	Oct. 31, 2018
Payables and Accruals [Abstract]
Accrued Liabilities	NOTE 6 – ACCRUED LIABILITIES As of October 31, 2018, the Company has the following accrued liabilities: Amount Accrued salary – officer $ 38,791 Credit card 9,608 Accrued interest 2,654 Total $ 51,053

Notes Payable

Notes Payable	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE As of October 31, 2018, the Company had outstanding notes payable totaling $18,600. The notes bear an interest rate of 5% per annum and are due upon demand giving 30 days written notice to the borrower. From inception through October 31, 2018, the Company recorded $464 in interest expense on the notes.	NOTE 7 – NOTE PAYABLE As of January 31, 2018 the Company received advances totaling $157,455 from an unrelated party, the advances are unsecured and bares an interest rate of 5% per annum, and is due upon demand giving 30 days written notice to the borrower. The Company has recorded accrued interest of $4,157 for the year ended January 31, 2018.

Gain on Settlement of Liability

Gain on Settlement of Liability	8 Months Ended
	Oct. 31, 2018
Notes to Financial Statements
Gain on Settlement of Liability	NOTE 8 – GAIN ON SETTLEMENT OF LIABILITY In May 2017, CLI, the accounting acquiree, entered into a Licensing Agreement with Affordable Green Washington LLC where the consideration was $2,100,000. On May 3, 2018 the CLI entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement was an aggregate total of 2,600,000 restricted Common Shares. On CLI’s balance sheet, a liability was recorded in the amount of $2,158,000, which was based on a fair value of $0.83 per share on the commitment date. As of the merger date, the liability balance of $1,300,000 was assumed by Apotheca in the merger. On August 7, 2018, Apotheca issued 2,600,000 in full satisfaction of the liability. On the date the shares were issued, the fair value of the shares were equal to $0.44. As a result, Apotheca recorded a gain on settlement of liability of $156,000.

Convertible Note Payable

Convertible Note Payable	8 Months Ended
	Oct. 31, 2018
Notes to Financial Statements
Convertible Note Payable	NOTE 9 – CONVERTIBLE NOTE PAYABLE On October 3, 2018, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company issued to Firstfire a Senior Convertible Promissory Note (“Note”) in the aggregate principal amount of $300,000. The Note The Company received net proceeds of $243,900 after a $24,000 original note discount and $32,100 of financing costs. The Note has a maturity date of October 3, 2019 and the Company has agreed to pay interest on the unpaid principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in the Note. The outstanding principal amount of the Note is convertible into common stock at the lender’s option at $0.20 per share. The agreements contain down-round protection in the event the Company issues common stock at a lower price. In connection with the agreement, the Company issued detachable warrants to purchase 480,000 shares of the company’s common stock. The warrants have a strike price of $0.3125 and an expiration date of October 3, 2021. The warrants contain down-round protection in the event the Company issues common stock at a lower price. Accounting Considerations The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows: Allocation Compound embedded derivative $ 408,373 Derivative warrants 128,544 Day-one derivative loss (260,917 ) Financing fees (32,100 ) Net proceeds $ (243,900 ) The net proceeds of $243,900 were allocated to the compound embedded derivative and derivative warrants. This resulted in a day-one derivative loss of $260,917. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $300,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $8,313. The carrying value of the Note as of October 31, 2018 amounted to $8,313.

Derivative Financial Instrument

Derivative Financial Instruments	8 Months Ended
	Oct. 31, 2018
Investments, All Other Investments [Abstract]
Derivative Financial Instruments	NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of October 31, 2018 and the amounts that were reflected in income related to derivatives for the period ended: October 31, 2018 The financings giving rise to derivative financial instruments Indexed Shares Fair Values Compound embedded derivative 301,898 $ (439,548) Derivative warrants 480,000 (140,112) Total 781,898 $ (579,660) The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended October 31, 2018 and for the period from February 26, 2018 (Inception) through to October 31, 2018: The financings giving rise to derivative financial instruments and the income effects: Three Months Ended December 31, 2013 Compound embedded derivative $ (31,175 ) Derivative warrants (11,568 ) Day-one derivative loss (260,917 ) Total gain (loss) $ (303,660 ) The Company’s face value $300,000 Secured Convertible Promissory Note and Detachable Warrants issued on October 3, 2018 gave rise to derivative financial instruments. The Notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option. Additionally the detachable warrants contained terms and features that gave rise to derivative liability classification. Current accounting principles that are provided in ASC 815 - Derivatives and Hedging Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities: Inception October 31, 2018 Quoted market price on valuation date $0.41 $0.44 Contractual conversion rate $0.20 $0.20 Contractual term to maturity 1.00 Year 0.92 Years Market volatility: Equivalent Volatility 163.10% 152.57% Interest rate 5.0% 5.0% The Company has selected the Black Scholes Merton valuation technique to fair value the detachable warrants because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives. Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities: Inception October 31, 2018 Quoted market price on valuation date $0.41 $0.44 Contractual strike price $0.3125 $0.3125 Range of effective contractual conversion rates -- -- Contractual term to maturity 3.00 Year 2.93 Years Market volatility: Volatility 166.14% 164.78% Risk-free interest rate 2.94% 2.93% The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018. October 31, 2018 Balances at February 26, 2018 (Company Inception) $ -- Issuances: Compound embedded derivative 408,373 Detachable warrants 128,544 Changes in fair value inputs and assumptions reflected in income 42,743 Balances at October 31 $ 579,660

Lease Obligation

Lease Obligation	8 Months Ended
	Oct. 31, 2018
Debt Disclosure [Abstract]
Lease Obligation	NOTE 11 –LEASE OBLIGATION On August 1, 2018, the Company entered into a lease agreement with Nuvus Gro Corp, a related party. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of October 31, 2018, the Company recorded $19,224 in rent expense related to this agreement. The Companies remaining lease obligation is as follows: Period Amount Due Fiscal Year Ended January 31, 2019 $ 19,224 Fiscal Year Ended January 31, 2020 44,856 Total $ 64,080

Common Shares to be Issued

Common Shares to be Issued	8 Months Ended
	Oct. 31, 2018
Other Liabilities Disclosure [Abstract]
Common Shares to be Issued	NOTE 12 –COMMON SHARES TO BE ISSUED From inception through October 31, 2018, the Company received cash totaling $73,700 in exchange for 184,250 shares of common stock at $0.40 per share. As of October 31, 2018 the shares had not been issued. As such, the value of $73,700 was recorded in equity under shares to be issued, common shares.

Equity

Equity	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Equity [Abstract]
Equity	NOTE 13 –EQUITY The Company has authorized 600,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of October 31, 2018, the company had 113,914,000 shares of common stock issued and outstanding.	NOTE 8 –EQUITY The Company has authorized 600,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of January 31, 2018 and 2017, the company had 50,340,000 shares of common stock issued and outstanding.

Forward Stock Split

Forward Stock Split	12 Months Ended
	Jan. 31, 2018
Notes to Financial Statements
Forward Stock Split	NOTE 9 –FORWARD STOCK SPLIT On June 26, 2017 FINRA approved a 6 to 1 forward split, all numbers reflected in the Financial Statements account for the forward split and have been retroactively adjusted.

Subsequent Events

Subsequent Events	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 - SUBSEQUENT EVENTS Share issuances Subsequent to the reporting period, the Company issued 300,000 shares to its President Sam Talari for a bonus.	NOTE 10 - SUBSEQUENT EVENTS On May 3, 2018 Cannabis Leaf, Inc. (the Registrant) entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties, and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement is an aggregate total of 2,600,000 Restricted Common Shares. On April 26, 2018 Cannabis Leaf, Inc. (the Registrant) provided a Notice of Termination to Green Venture Capital Inc., Pursuant to the Letter of Intent entered into by Cannabis Leaf, Inc. and Green Venture Capital, Inc. on October 24, 2017 and pursuant to Section L. of the Letter of Intent, No Consideration has been paid to date. On March 6, 2018, An Agreement for Plan of Merger (the "Agreement") was entered into by Cannabis Leaf Incorporated. ("Cannabis Leaf"), a Nevada Corporation, and Apotheca Biosciences, Inc. ("Apotheca Biosciences"), a Nevada Corporation. Such Agreement will result in the merger of Apotheca Biosciences into Cannabis Leaf with the Corporation to survive as Apotheca Biosciences. Apotheca Biosciences and Cannabis Leaf entered into the Merger Agreement where Cannabis Leaf agreed to issue Apotheca Biosciences sixty million (60,000,000) common shares of Cannabis Leaf in exchange for all of the shares of Apotheca Biosciences. This issuance will result in a change in control of Cannabis Leaf. Under the Agreement, upon closing, Apotheca Biosciences will receive the immediate right to the appointment of the directors and officers of the surviving corporation by the resignation of the existing officer of Cannabis Leaf and the simultaneous appointment of the officers and two additional directors. On March 20, 2018 the Company issued 831,330 and 142,670 restricted common shares in settlement of debt in the amounts of $166, 266 and $28,534 respectively. On April 24, 2018 the Company Issued a 60,000,000 restricted common shares as the consideration, as part of the terms and conditions of the Merger Agreement between Cannabis Leaf and Apotheca Biosciences.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited and have not been reviewed. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.	Basis of Presentation The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP") and presented in US dollars. The fiscal year end is January 31.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all liquid investments with a maturity of three months or less from the date of purchase that are readily convertible into cash to be cash equivalents. As of January 31, 2018 and 2017, cash and cash equivalents was $0 and $498, respectively.
Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.	Financial Instruments The Company's financial instruments consist primarily of cash, accounts payable and accrued liabilities, notes payable and due to related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
Deferred Income Taxes and Valuation Allowance		Deferred Income Taxes and Valuation Allowance The Company accounts for income taxes under ASC 740, "Income Taxes".
Net Loss Per Share of Common Stock	Basic and Diluted Earnings Per Share Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share there were no potentially dilutive securities.	Net Loss Per Share of Common Stock The Company follows - ASC Topic 260, "Earnings per Share" Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock or other contracts to issue common stock resulting in the issuance of common stock that would then share in the Company's earnings subject to anti-dilution limitations. In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact. For the year ended January 31, 2018 and 2017, the Company did have any potentially dilutive securities.
Contingencies		Contingencies The Company follows ASC 450-20, "Loss Contingencies"
Revenue Recognition		Revenue Recognition , "Revenue from Contracts with Customers."
Recent Accounting Pronouncements	New Accountin Pronouncements In February 2016, FASB issued ASC 842 that requires lessees to recognize lease assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months. The update, which supersedes existing lease guidance, will continue to classify leases as either finance or operating, with the classification determining the pattern of expense recognition in the income statement. The ASU will be effective for annual and interim periods beginning January 1, 2019, with early adoption permitted, and is applicable on a modified retrospective basis with various optional practical expedients. The Company is assessing the impact of this standard. In May 2014, ASU 2014-09 was issued related to revenue from contracts with customers. The ASU was further amended in August 2015, March 2016, April 2016, and May 2016 by ASU 2015-14, 2016-08, 2016-10 and 2016-12. The new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition. In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted. The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)", "Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date," Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing," "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients," In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" In January 2017, the FASB issued ASU No. 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business." Management has considered all recent accounting pronouncements issued. The Company's management believes that these recent pronouncements will not have a material effect on the Company's financial statements.

Merger (Tables)

Merger (Tables)	8 Months Ended
	Oct. 31, 2018
Business Combinations [Abstract]
Merger	The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization. Common Stock Shares Amount Additional Paid in Capital Shares to be issued Accumulated (Deficit) Total Balances, February 26, 2018 - $ - $ - $ - $ - $ - Shares issued by Apotheca in exchange for services ($.001 par value) 60,000,000 6,000 - - - 6,000 Recapitalization on August 2, 2018 51,314,000 105,314 (1,444,587 ) (1,339,273 ) Shares issued in satisfaction of accrued liability (license settlement) 2,600,000 2,600 1,141,000 1,144,000 Shares to be issued 73,700 73,700 Net loss from February 26, 2018 through October 31, 2018 (405,339 ) (405,339 ) Balances, October 31, 2018 113,914,000 $ 113,914 $ (303,187 ) $ 73,7000 $ (405,339 ) $ (520,912 )

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	8 Months Ended
	Oct. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued liabilities	As of October 31, 2018, the Company has the following accrued liabilities: Amount Accrued salary – officer $ 38,791 Credit card 9,608 Accrued interest 2,654 Total $ 51,053

Convertible Note Payable (Table

Convertible Note Payable (Tables)	8 Months Ended
	Oct. 31, 2018
Notes to Financial Statements
Convertible Note Payable	Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows: Allocation Compound embedded derivative $ 408,373 Derivative warrants 128,544 Day-one derivative loss (260,917 ) Financing fees (32,100 ) Net proceeds $ (243,900 )

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	8 Months Ended
	Oct. 31, 2018
Investments, All Other Investments [Abstract]
Derivative financial instruments	The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of October 31, 2018 and the amounts that were reflected in income related to derivatives for the period ended: October 31, 2018 The financings giving rise to derivative financial instruments Indexed Shares Fair Values Compound embedded derivative 301,898 $ (439,548) Derivative warrants 480,000 (140,112) Total 781,898 $ (579,660)
Derivative financial instruments and income effects	The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended October 31, 2018 and for the period from February 26, 2018 (Inception) through to October 31, 2018: The financings giving rise to derivative financial instruments and the income effects: Three Months Ended December 31, 2013 Compound embedded derivative $ (31,175 ) Derivative warrants (11,568 ) Day-one derivative loss (260,917 ) Total gain (loss) $ (303,660 )
Embedded derivative	Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities: Inception October 31, 2018 Quoted market price on valuation date $0.41 $0.44 Contractual conversion rate $0.20 $0.20 Contractual term to maturity 1.00 Year 0.92 Years Market volatility: Equivalent Volatility 163.10% 152.57% Interest rate 5.0% 5.0% Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities: Inception October 31, 2018 Quoted market price on valuation date $0.41 $0.44 Contractual strike price $0.3125 $0.3125 Range of effective contractual conversion rates -- -- Contractual term to maturity 3.00 Year 2.93 Years Market volatility: Volatility 166.14% 164.78% Risk-free interest rate 2.94% 2.93%
Changes in fair value inputs and assumptions	The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018. October 31, 2018 Balances at February 26, 2018 (Company Inception) $ -- Issuances: Compound embedded derivative 408,373 Detachable warrants 128,544 Changes in fair value inputs and assumptions reflected in income 42,743 Balances at October 31 $ 579,660

Lease Obligation (Tables)

Lease Obligation (Tables)	8 Months Ended
	Oct. 31, 2018
Debt Disclosure [Abstract]
Schedule of Future Minimum Rental Payments	The Companies remaining lease obligation is as follows: Period Amount Due Fiscal Year Ended January 31, 2019 $ 19,224 Fiscal Year Ended January 31, 2020 44,856 Total $ 64,080

Significant Accounting Polici_3

Significant Accounting Policies (Details Narratives) - USD ($)	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017	Apr. 30, 2018	Feb. 25, 2018	Jan. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 168,462	$ 0	$ 489	$ 0	$ 0	$ 3,358
Potentially dilutive securities	0	0	0

Merger (Details)

Merger (Details)	8 Months Ended
	Oct. 31, 2018USD ($)shares
Common Stock
Beginning Balance, Value
Beginning Balance, Shares
Shares issued by Apotheca in exchange for services, Value	$ 6,000
Shares issued by Apotheca in exchange for services, shares | shares	60,000,000
Recapitalization, Value	$ 105,314
Recapitalization, Shares | shares	51,314,000
Shares issued in satisfaction of accrued liability (license settlement), Value	$ 2,600
Shares issued in satisfaction of accrued liability (license settlement), shares | shares	2,600,000
Ending Balance	$ 113,914
Ending Balance, Shares | shares	113,914,000
Additional Paid-In Capital
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Recapitalization, Value	(1,444,587)
Shares issued in satisfaction of accrued liability (license settlement), Value	1,141,000
Ending Balance	(303,187)
Shares to be issued
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Shares to be issued	73,700
Ending Balance	737,000
Accumulated (Deficit)
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Net loss	(405,339)
Ending Balance	(405,339)
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value	6,000
Recapitalization, Value	(1,339,273)
Shares issued in satisfaction of accrued liability (license settlement), Value	1,144,000
Shares to be issued	73,700
Net loss	(405,339)
Ending Balance	$ (520,912)

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017	Apr. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 168,462	$ 168,462			$ 0
Negative working capital	520,912	520,912			32,242
Net loss	(313,118)	(405,339)	$ (195,780)	$ (17,786)
Accumulated deficit	$ (405,339)	$ (405,339)	$ (289,831)	$ (94,051)	$ (38,242)

Deposit On License Impairment (

Deposit On License Impairment (Details Narrative) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Deposit on license	$ 142,455	$ 0
Impairment of deposit on license	79,975	$ 0
License and permits	62,480
License With Affordable Green LLC [Member]
Deposit on license	142,455
Impairment of deposit on license	79,975
License and permits	$ 62,480
Deposit on license terms	All funds used for the deposit on license were received by way of short term loans that bear a 5% annual interest rate.

Note Payable From Related Par_2

Note Payable From Related Party (Details Narrative) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2018
Short-term Debt [Line Items]
Loans payable - related parties	$ 47,134	$ 28,534
Proceeds from note payable - related party	18,600	472
Imputed interest	2,677	3,015
Accrued interest			$ 2,654
Related Party [Member] | Note Payable [Member]
Short-term Debt [Line Items]
Loans payable - related parties	47,134	$ 28,534
Proceeds from note payable - related party	$ 18,600
Notes payable description	The advances are unsecured, of which $28,534 is non-interest bearing and is due upon demand giving 30 days written notice to the borrower. A balance of $18,600 was received from a related party and bares an interest rate of 5% per annum, and is due upon demand giving 30 days written notice to the borrower.
Interest rate	5.00%
Imputed interest	$ 2,677
Accrued interest	$ 710

Accounts Payable - Related Pa_2

Accounts Payable - Related Party (Details Narrative) - USD ($)	Oct. 15, 2018	Oct. 31, 2018	Apr. 30, 2018
Notes to Financial Statements
Accounts payable - related party		$ 3,724	$ 0
Monthly office rent		$ 6,408
Rent paid	$ 2,684
Rent	$ 3,724

Related Party Contributions (De

Related Party Contributions (Details Narrative) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Disclosure Related Party Contributions Abstract
Related party contribution	$ 3,500	$ 8,050
Related party description	These contributions are not to be repaid and are recorded under additional paid in capital.

Accrued Liabilities (Details Na

Accrued Liabilities (Details Narrative) - USD ($)	Oct. 31, 2018	Apr. 30, 2018	Jan. 31, 2018
Payables and Accruals [Abstract]
Accrued salary - officer	$ 38,791
Credit card	9,608
Accrued interest	2,654
Total	$ 51,053	$ 30,000	$ 0

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	8 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018	Apr. 30, 2018
Short-term Debt [Line Items]
Notes payable	$ 18,600		$ 0
Proceeds from loan		$ 157,455
Accrued interest	2,654
Note Payable [Member]
Short-term Debt [Line Items]
Notes payable	$ 18,600
Interest rate	5.00%
Interest expense on notes	$ 464
Note Payable - Unrelated Party [Member]
Short-term Debt [Line Items]
Interest rate		5.00%
Proceeds from loan		$ 157,455
Notes payable description		The advances are unsecured and bares an interest rate of 5% per annum, and is due upon demand giving 30 days written notice to the borrower.
Accrued interest		$ 4,157

Gain on Settlement of Liabili_2

Gain on Settlement of Liability (Details Narrative) - USD ($)	Aug. 07, 2018	May 03, 2018	May 31, 2017	Oct. 31, 2018	Oct. 31, 2018	Mar. 26, 2018
Liability						$ 1,300,000
Gain on settlement of liability				$ 156,000	$ 156,000
Licensing Agreement | Affordable Green Washington [Member]
Consideration			$ 2,100,000
Licensing Agreement | CLI [Member]
Shares issued to satisfy liability		2,600,000
Liability		$ 2,158,000
Fair value of share		$ 0.83
Settlement and Release Agreement [Member]
Shares issued to satisfy liability	2,600,000
Gain on settlement of liability	$ 156,000
Fair value of share	$ 0.44

Convertible Note Payable (Detai

Convertible Note Payable (Details)	8 Months Ended
	Oct. 31, 2018USD ($)
Notes to Financial Statements
Compound embedded derivative	$ 408,373
Derivative warrants	128,544
Day-one derivative loss	(260,917)
Financing fees	(32,100)
Net proceeds	$ (243,900)

Convertible Note Payable (Det_2

Convertible Note Payable (Details Narrative) - USD ($)	Oct. 03, 2018	Oct. 31, 2018	Apr. 30, 2018
Convertible Note Payable		$ 8,313	$ 0
Proceeds from convertible notes payable		243,900
Financing costs		32,100
Day-one derivative loss		$ (260,917)
Secured Convertible Promissory Note Agreement [Member]
Convertible Note Payable	$ 300,000
Original issue discount	$ 24,000
Interest Rate	5.00%
Maturity Date	Oct. 3, 2019
Option per share	$ 0.20
Strike price	$ 0.3125
Expiration date	Oct. 3, 2021
Amortization expense	$ 8,313

Derivative Financial Instrume_3

Derivative Financial Instruments (Details)	8 Months Ended
	Oct. 31, 2018USD ($)shares
Derivative Financial Instruments Abstract
Compound embedded derivative, Indexed Shares | shares	301,898
Compound embedded derivative, Fair values | $	$ (439,548)
Derivative warrants, Indexed Shares | shares	480,000
Derivative warrants, Fair values | $	$ (140,112)
Total, Indexed Shares | shares	781,898
Total, Fair values | $	$ (579,660)

Derivative Financial Instrume_4

Derivative Financial Instruments (Details 1) - USD ($)	3 Months Ended	8 Months Ended
	Oct. 31, 2018	Oct. 31, 2018
Derivative Financial Instruments Abstract
Compound embedded derivative		$ (31,175)
Derivative warrants		(11,568)
Day-one derivative loss		(260,917)
Total gain (loss)	$ (303,660)	$ (303,660)

Derivative Financial Instrume_5

Derivative Financial Instruments (Details 2) - Monte Carlo Simulations process [Member] - $ / shares	Feb. 25, 2018	Oct. 31, 2018
Quoted market price on valuation date	0.41	0.44
Contractual conversion rate	$ 0.20	$ 0.20
Contractual term to maturity	1 year	11 months 1 day
Equivalent Volatility	163.10%	152.57%
Interest rate	5.00%	5.00%

Derivative Financial Instrume_6

Derivative Financial Instruments (Details 3) - Black Scholes Merton process [Member] - $ / shares	Feb. 25, 2018	Oct. 31, 2018
Quoted market price on valuation date	0.41	0.44
Contractual strike price	0.31	0.31
Range of effective contractual conversion rates	$ 0	$ 0
Contractual term to maturity	3 years	2 years 11 months 4 days
Volatility	166.14%	164.78%
Risk-free interest rate	2.94%	2.93%

Derivative Financial Instrume_7

Derivative Financial Instruments (Details 4)	8 Months Ended
	Oct. 31, 2018USD ($)
Derivative Financial Instruments Abstract
Balance at beginning	$ 0
Issuances:
Compound embedded derivative	408,373
Detachable warrants	128,544
Changes in fair value inputs and assumptions reflected in income	42,743
Balances at end	$ 579,660

Derivative Financial Instrume_8

Derivative Financial Instruments (Details Narrative) - USD ($)	Oct. 31, 2018	Oct. 03, 2018	Apr. 30, 2018
Convertible Note Payable	$ 8,313		$ 0
Secured Convertible Promissory Note Agreement [Member]
Convertible Note Payable		$ 300,000

Lease Obligation (Details)

Lease Obligation (Details)	Oct. 31, 2018USD ($)
Leases [Abstract]
Fiscal Year Ended January 31, 2019	$ 19,224
Fiscal Year Ended January 31, 2020	44,856
Total	$ 64,080

Lease Obligation (Details Narra

Lease Obligation (Details Narrative)	8 Months Ended
	Oct. 31, 2018USD ($)
Leases [Abstract]
Monthly office rent	$ 6,408
Rent expenses	19,224
Rent deposit	$ 6,000

Common Shares to be Issued (Det

Common Shares to be Issued (Details Narrative) - USD ($)	8 Months Ended
	Oct. 31, 2018	Apr. 30, 2018
Other Liabilities Disclosure [Abstract]
Common stock issued in exchange for cash, value	$ 73,700
Common stock issued in exchange for cash, share	184,250
Share Price	$ 0.40
Shares to be issued, common shares	$ 73,700	$ 0

Equity (Details Narrative)

Equity (Details Narrative) - $ / shares	3 Months Ended
	Oct. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017
Equity [Abstract]
Common stock voting rights	Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.
Common stock, par value per share	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	200,000,000	600,000,000	600,000,000
Common stock, shares issued	113,914,000	111,314,000	50,340,000	50,340,000
Common stock, shares outstanding	113,914,000	111,314,000	50,340,000	50,340,000

Forward Stock Split (Details Na

Forward Stock Split (Details Narrative)	Jun. 26, 2017
Common Stock
Forward split description	On June 26, 2017 FINRA approved a 6 to 1 forward split, all numbers reflected in the Financial Statements account for the forward split and have been retroactively adjusted.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 03, 2018	Apr. 24, 2018	Mar. 20, 2018	Mar. 06, 2018	Nov. 01, 2018	Oct. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017
Subsequent Event [Line Items]
Common stock, shares issued						113,914,000	111,314,000	50,340,000	50,340,000
Subsequent Event [Member] | Restricted Common Stock [Member] | ConvertibleDebtOneMember
Subsequent Event [Line Items]
Stock issued for settlement of debt, shares			142,670
Stock issued for settlement of debt, value			$ 28,534
Subsequent Event [Member] | Restricted Common Stock [Member] | Settlement Of Debt [Member]
Subsequent Event [Line Items]
Stock issued for settlement of debt, shares			831,330
Stock issued for settlement of debt, value			$ 166,266
Subsequent Event [Member] | Agreement For Plan Of Merger With Apotheca Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Merger agreement description				On March 6, 2018, An Agreement for Plan of Merger (the "Agreement") was entered into by Cannabis Leaf Incorporated. ("Cannabis Leaf"), a Nevada Corporation, and Apotheca Biosciences, Inc. ("Apotheca Biosciences"), a Nevada Corporation. Such Agreement will result in the merger of Apotheca Biosciences into Cannabis Leaf with the Corporation to survive as Apotheca Biosciences. Apotheca Biosciences and Cannabis Leaf entered into the Merger Agreement where Cannabis Leaf agreed to issue Apotheca Biosciences sixty million (60,000,000) common shares of Cannabis Leaf in exchange for all of the shares of Apotheca Biosciences. This issuance will result in a change in control of Cannabis Leaf. Under the Agreement, upon closing, Apotheca Biosciences will receive the immediate right to the appointment of the directors and officers of the surviving corporation by the resignation of the existing officer of Cannabis Leaf and the simultaneous appointment of the officers and two additional directors. On March 20, 2018 the Company issued 831,330 and 142,670 restricted common shares in settlement of debt in the amounts of $166, 266 and $28,534 respectively.
Subsequent Event [Member] | Agreement For Plan Of Merger With Apotheca Biosciences, Inc. [Member] | Restricted Common Stock [Member]
Subsequent Event [Line Items]
Stock issued as consideration for merger agreement, shares		60,000,000
Subsequent Event [Member] | Settlement And Release Agreement With AGH WA, LLC [Member]
Subsequent Event [Line Items]
Agreement description	On May 3, 2018 Cannabis Leaf, Inc. (the Registrant) entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties, and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement is an aggregate total of 2,600,000 Restricted Common Shares.
Subsequent Event [Member] | President [Member]
Subsequent Event [Line Items]
Common stock, shares issued					300,000